GlassScriptPhysician profile
David Andrew Svetec
NPI 1053343152
$4,080.16
in general payments reported to CMS, 2019-2025
41 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $142 · 2021: $876 · 2022: $735 · 2023: $704 · 2024: $902 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $458.05 | 2019-2025 | Erleada, Akeega, Balversa |
| Astrazeneca Pharmaceuticals LP | $377.77 | 2021-2024 | Lynparza |
| Pfizer INC. | $309.72 | 2021-2025 | |
| Intuitive Surgical, INC. | $290.41 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $287.26 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $274.53 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $264.75 | 2019-2024 | Xtandi |
| Merck Sharp & Dohme LLC | $173.90 | 2021-2024 | Keytruda, Lynparza |
| Teleflex LLC | $161.60 | 2024 | Urolift |
| Procept Biorobotics Corporation | $147.15 | 2024 | Aquabeam System |
| Sumitomo Pharma America, INC. | $133.34 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $128.74 | 2024-2025 | |
| Coloplast Corp | $103.83 | 2021-2024 | Speedicath |
| Urovant Sciences INC | $101.54 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $99.51 | 2022-2025 | Pylarify |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Svetec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.